Adaptive Biotechnologies Corp. (Nasdaq: ADPT) on Thursday launched ImmuneCODE with Microsoft Corp. (Nasdaq: MSFT) to begin sharing one of the largest, most detailed views of the immune response to COVID-19 in real time based on de-identified data generated from thousands of COVID-19 blood samples from patients around the globe. The open database contains detailed information on the extraordinarily diverse set of T…
Read More
In early March, developmental biologist Lee Niswander’s lab at the University of Colorado Boulder had just successfully generated strains of mice that lacked certain sections of a gene involved in brain development. Some strains had taken nearly a year and a half to develop, and preliminary data suggested that the gene was essential to survival. But the surging COVID-19 pandemic…
Read More
Scientists from the Seattle Children’s Research Institute and the Benaroya Research Institute have found a potential way to turn off the destructive autoimmune response in Type 1 diabetes—and it involves editing the genes of patients’ own T cells. The team showed that by gene-editing CD4+ T cells to express a protein called FOXP3, they could turn the cells into cells with…
Read More
It is increasingly clear that the human microbiome — the trillions of microbes that live in and on us — directly affects our health. In findings published in the journal PNAS, ISB researchers highlight the dichotomy between two common gut microbiome bacterial genera — Bacteroides and Prevotella. Humans who have a lot of one in their gut tend to have very little of the other, and vice…
Read More
Over the last four years, Benaroya Research Institute at Virginia Mason (BRI) and Seattle Children’s Research Institute (SCRI) have been developing a novel approach to engineer a person’s own immune cells to target and treat type 1 diabetes (T1D), with the goal of eliminating the need for insulin injections. Currently, people with T1D must inject themselves with insulin in order to stay alive. With…
Read More
Athira Pharma changed its name last year to reflect its focus on regenerative medicine. Now, it’s snagged $85 million to advance those medicines, which includes bankrolling a phase 2/3 trial in Alzheimer’s for its lead asset. Formerly known as M3 Biotechnology, the Seattle-based biotech landed on its new moniker, derived from the Arabic word meaning “a force” or “energy,” in…
Read More
Seattle’s Infectious Disease Research Institute is working with Houston’s Baylor College of Medicine to multiply the doses of a potential COVID-19 vaccine by 30 to 100 times. Other partners in the effort include Seattle-based PATH and Texas Children’s Hospital Center for Vaccine Development. If the project proceeds as planned, Baylor and its partners could repurpose a vaccine candidate originally created to counter a different coronavirus-based disease known…
Read More
About 1% of kids who visited a Seattle hospital in April had been infected with the novel coronavirus, according to the first large-scale survey for antibodies in children. The study also found most of the youngsters developed a robust immune response, an encouraging sign for a future vaccine. “If children can respond to the virus, then children can respond to…
Read More
People with autism spectrum disorder, or ASD, may experience sensory hypersensitivity more often than people without ASD, according to the National Autism Association. Among other responses, this hypersensitivity can lead to “sensory overload,” when sensory systems like vision or hearing are “overwhelmed” by stimuli. Scientists do not fully understand the differences in how sensory systems perceive and process stimuli in…
Read More